PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: M&A
Pharma to Flash the Cash to Counter Bleak Short-Term Outlook
Nearly two-thirds of US senior pharmaceutical executives surveyed by last month foresee a ‘full economic recovery’ by the end of 2013, with more than half of these pointing to an upturn in the industry’s fortunes by the end of next year.
However, 27 percent of the 100 executives interviewed by KPMG for its Industry Pulse Survey [...]
With Cephalon Buy, Teva Bets on Brand Drugs and More In-House Innovation
If commodity generics and in-licensing deals are all the rage, then Teva just strapped on a fanny pack with its $6.8 billion acquisition of Cephalon.
The deal is expected to skyrocket Teva’s brand drug portfolio to $7 billion in annual sales, making Teva “not only the world’s largest generics company, but also one of the world’s [...]
Pfizer Adds FoldRx to its Specialty Care Unit
Pfizer on Wednesday announced that it acquired a small rare-disease drug firm, FoldRx, for an undisclosed sum of money.
Pfizer spokeswoman Gwen Fischer told Pharm Exec that the deal came together in a matter of weeks, and that FoldRx will be fully incorporated into Pfizer’s research division. All of FoldRx’s employees are expected to become Pfizer [...]
Genzyme Snubs Sanofi Offer
Less than 24 hours after offering to purchase Genzyme for $18.5 billion, Sanofi-Aventis was sent a letter of rejection from the biotech firm’s board of directors stating that the offer just wasn’t worth it.
“Without exception, each member of the Genzyme board believes this is not the right time to sell the company, because your opportunistic [...]
Putting the M Back in M&A